Ian E. Krop, MD, PhD

Dana-Farber Cancer Institute

Boston, Massachusetts


COVID-19 and the Use of HER2-Targeted Therapy for MBC

June 29, 2021

The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.